Key result
Statin use during long-term vitamin K antagonist treatment for venous thromboembolism did not significantly increase the risk of major or clinically-relevant non-major bleeding (adjusted HR 0.91).
Why the study?
Does statin use increase bleeding risk in adult patients taking vitamin K antagonists for venous thromboembolism?
Cohort (n=681)
Yes
Does statin use increase bleeding risk in adult patients taking vitamin K antagonists for venous thromboembolism?
Hazard Ratio: 0.91 (95% CI 0.43–1.93)
Absolute Event Rate: 10.7% vs 9.8%
p-value: p=0.843
Statin use does not appear to increase the risk of bleeding in patients receiving long-term vitamin K antagonist therapy for venous thromboembolism.
No increased bleeding risk seen with statins plus VKAs in VTE; leaves open need for RCT confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Riva et al. (2015) conducted a cohort in Venous thromboembolism (n=681). Statin use vs. Non-statin users was evaluated on Composite of major bleeding (MB) and clinically-relevant non-major bleeding (CRNMB) during VKA treatment and up to three days after discontinuation (Adjusted HR 0.91, 95% CI 0.43-1.93, p=0.843). Statin use during long-term vitamin K antagonist treatment for venous thromboembolism did not significantly increase the risk of major or clinically-relevant non-major bleeding (adjusted HR 0.91).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: